Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 27CNS 2Sarcoma 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Glioblastoma 4Glioma 3Breast Neoplasms 3Brain Neoplasms 3Cholangiocarcinoma 2Central Nervous System Neoplasms 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1Lymphoma 1Colonic Neoplasms 1Chondrosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 4Nivolumab 3Gemcitabine 3Fluorodeoxyglucose F18 3olutasidenib 2olaparib 2durvalumab 2Specimen Handling 2FAPI-46 2Cisplatin 2ulixertinib 1pembrolizumab 1ivosidenib 1entrectinib 1enasidenib 1cobimetinib 1alectinib 1Topotecan 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1Molecular Diagnostic Techniques 1Metformin 1Ipilimumab 1Immunotherapy 1Folfox protocol 1Fluoresceins 1Fluorescein 1Drug Therapy 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Cholangiocarcinoma × durvalumab × CNS × Clear all
NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

Eli Lilly and Company

Phase 1 Active not recruiting
200 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT03991832 2024-07-18

SOLID

University Health Network, Toronto

Phase 2 Recruiting
58 enrolled
CNSGastrointestinal

Glioma, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡